Kalos Therapeutics
San Diego, California, United States
About Kalos Therapeutics
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small-molecule compounds.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $958.0K
- Last round: Convertible Note (Feb 2013)
- Website: kalostherapeutics.com
- Phone: +1 858 552 6890
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/kalos-therapeutics-2471278 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.